Til this month, I believe all trial participants have been kept on the same dose from the start of Part B. This is merely an extension of Part B not so much a new trial w/new parameters. That said, this month, patients on 10mg have been allowed to move up to 20mg. I get that b/c the trial has shown that 14mg is the minimum theapeutic dose. I'm sure those 10mg patients want to be taking more than 14mg. Not sure why 20mg was chosen for them to move up to and not 30 or 40mg. I'd be shocked if only 20mg turns out to be the optimal dose. Maybe Anavex wants to bump them up to just 20mg and observe for effect before bumping them up another 10mg two more times.
News 
Market Data 
Discover 
